Rocket Lab (RKLB) is a strong long-term investment, with 2025 growth fueled by Neutron rocket launches and analysts' bullish ...
Goldman Sachs analyst Richard Law lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $15 from $29 and keeps a Neutral rating ...
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Rocket Lab USA, Inc. (“Rocket ...
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Lab ...
Rocket Lab (NASDAQ: RKLB) stock got thrown for a loop Friday morning, first crashing more than 18% in response to a disappointing earnings report, then recovering as investors took time to digest the ...
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rocket Lab USA, Inc. ("Rocket Lab" or the "Company") (NASDAQ: RKLB) and reminds investors of the ...
Hosted on MSN13h
Rocket Lab Stock Is Down 30% in the Last Month. Should You Buy the Dip or Run Far Away?Rocket Lab (RKLB) wrapped up 2024 on a high note, delivering record-breaking revenue and impressive year-over-year growth.
The 'Flatellite' model is designed to help companies and government agencies launch and operate large satellite ...
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Lab ...
The S&P 500 Index ($SPX) (SPY) today is up +0.05%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.29%, and the Nasdaq ...
Stock futures edged higher on Friday as President Trump’s latest announcement of new tariffs and China’s vow to retaliate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback